Trevi Therapeutics Obtains $25,000,000 Series B Round

  • Feed Type
  • Date
    6/4/2014
  • Company Name
    Trevi Therapeutics
  • Mailing Address
    195 Church Street 14th Floor New Haven, CT 06510 USA
  • Company Description
    Trevi Therapeutics, Inc. is a drug development company founded in 2011 focused on developing T111 for the severe chronic itching condition known as pruritus. Pruritus is manifested in various dermatological, metabolic, hematologic and neuronal conditions.
  • Website
    http://www.trevitherapeutics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The Company plans to use the funding for the initiation of pivotal trials in two severe itch conditions: uremic pruritus and prurigo nodularis. The Company recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was shown to be well tolerated in patients on hemodialysis with itch and established proof-of-concept in uremic pruritus. The Company intends to initiate both pivotal trials in the third quarter of this year, and expects to have top-line results in the second half of 2015.
  • M&A Terms
  • Venture Investor
  • Venture Investor